After completing her neurology training at Hospital Ramon y Cajal in Madrid, Dr Delia Chaverri entered as staff Neurologist at the Hospital Carlos III. There she combined her duty as general neurologist with a special involvement with ALS patients. With Dr J. Mora, she established the first ALS Unit in Spain. Devoted mainly to patient care, she has participated in a large number of ALS international clinical trials. In 2014, the Hospital Carlos III merged with Hospital La Paz, forming a single institution where she has been coordinating the ALS unit since 2016. More than 300 patients are treated regularly at the unit by a high level multidisciplinary team.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.